In inflammatory bowel disease, when should antidiarrheal agents be used?

• A. Antidiarrheal agents once infectious etiology is ruled out
• B. Cholestyramine is effective treatment for steatorrhea
• C. patients with diarrhea should be treated with prebiotics
• D. pharmacological therapy is withheld until diarrhea exceeds 1 L/day

Answer: (A)

In inflammatory bowel disease, antidiarrheal agents are best used only after infectious etiologies have been ruled out. Reducing gut motility during an active infection can mask symptoms and increase the risk of complications like toxic megacolon, so clinicians first test for infections (such as C. difficile) and ensure the diarrhea isn’t due to an infection before using agents like loperamide or diphenoxylate. Once infection is excluded, these medications can help decrease stool frequency and improve comfort.

The other statements don’t fit as guidance for antidiarrheal use in IBD: cholestyramine is a bile acid sequestrant used for bile acid–related diarrhea, not as a general antidiarrheal for steatorrhea; prebiotics are not established as standard therapy for IBD-related diarrhea; and withholding pharmacologic therapy until diarrhea exceeds a specific volume isn’t a typical practice—treatment decisions depend on infection status, disease activity, and hydration/electrolyte management rather than a fixed volume threshold.